Irbesartan Heumann

Irbesartan, the active ingredient in Irbesartan Heumann, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure and to slow the progression of kidney disease in patients with diabetes.

GNH USA supplies Irbesartan Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system. - Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile. - Diabetic nephropathy: slows progression of renal impairment in patients with type 2 diabetes. - Heart failure: used as part of therapy to improve symptoms and reduce hospitalisation in patients intolerant to ACE inhibitors.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Acute kidney injury - Hyperkalemia

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly: ensure target levels are achieved without excessive drop. - Assess renal function: check serum creatinine and eGFR at baseline and periodically. - Check serum potassium: avoid hyperkalaemia, especially when combined with potassium‑sparing agents. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid in patients with known hypersensitivity to irbesartan or other ARBs. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Irbesartan may interact with several medicines. Review the following before co‑administration. Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction. - Dual ARB/ACE‑inhibitor therapy: heightened risk of hypotension and renal impairment. - Potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - Lithium: can raise lithium concentrations, leading to toxicity. - NSAIDs (high dose or chronic use): may precipitate acute kidney injury.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: monitor for excessive blood pressure reduction. - Antidiabetic agents: observe glucose control as blood pressure changes may affect insulin sensitivity.